As a pharmacist, I have lost count of the number of conversations that begin with a quiet admission. Someone leans in at the counter and says, "I've been thinking about Wegovy, but I just can't do needles." They often say it apologetically, as though a fear of injections is something to be embarrassed about. It is not. It is one of the most common reasons I see people delay or avoid treatment altogether, and until recently, there was no licensed oral alternative I could point them towards for weight management.
That changed on 11 June 2026, when the MHRA approved the semaglutide (Wegovy) tablet, the UK's first GLP-1 receptor agonist tablet for weight loss and weight management. So, will the tablet be better for needle-phobic patients? For many, honestly, yes. It removes the single biggest barrier standing between them and treatment. But it is not automatically the right choice for everyone, and the tablet asks something different of you in return. Let me talk you through it properly, as




